Gilead Sciences Gains Orphan Drug Status For Liver Treatment, Shares Move Higher

By: via Benzinga
Gilead Sciences, Inc. (NASDAQ: GILD) obtained orphan drug status on Monday for its simtuzumab as a treatment for a rare disorder ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.